Nanobiotix has clarified that there are no ongoing takeover discussions, which has helped stabilize investor sentiment amid rising broader market conditions. The company is advancing its clinical pipeline, supported by significant milestone payments from a recent licensing agreement with Johnson & Johnson. This security in funding could enhance its value as it progresses toward potential product launches.
Nanobiotix reported positive Phase 1 results for JNJ-1900 in melanoma patients. Treatment showed a 47.4% objective response rate with a 100% DCR in irradiated tumors. Median overall survival for treated patients was 14.6 months. Nanobiotix established a co-development deal with Johnson & Johnson in 2023. NBTX stock surged 22.03% following the report of these results.
